Chinese biotech valuations likely hit as trailblazer’s Hong Kong shares sink – Reuters

Reuters
HONG KONG/SAN FRANCISCO (Reuters) – Biotech startups can expect more measured valuations should they list in Hong Kong, investors and bankers said, after shares of the first such firm to take advantage of rules allowing listings from pre-profit
Streamlined visit visa system opens door to more mainland Chinese tourists in Hong Kong, Macau and TaiwanSouth China Morning Post

all 7 news articles

…read more

Source:: Hong Kong News By Google News

Leave a Comment